Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829185) titled 'Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of Oklahoma
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
Intervention:
Drug: modified FOLFIRINOX
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 2026
Target Sample Size: 30
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07829185
...